Clinical Trial Detail

NCT ID NCT03564821
Title IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Ivosidenib

Age Groups: senior adult

Additional content available in CKB BOOST